Gideon Aweh
YOU?
Author Swipe
View article: Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings
Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings Open
Our findings demonstrated individuals with TD in LTC settings have a high comorbidity burden and polypharmacy, particularly for medications with anticholinergic properties. Further investigation is warranted to evaluate the impact of TD in…
View article: Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries
Demographic and Socio-Economic Disparities in the Outcomes Among Patients with NVAF Treated with Oral Anticoagulants: A Real-World Evaluation of Medicare Beneficiaries Open
Objectives: To assess the association between apixaban use and the risk of stroke/systemic embolism (SE) and major bleeding (MB) compared with other anticoagulants (OACs) across demographic and socio-economic subgroups in the treatment of …
View article: Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries
Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries Open
Introduction Anticoagulation therapies are essential component of disease management for patients with atrial fibrillation (AF). Direct-acting oral anticoagulants (DOACs), such as apixaban, rivaroxaban, and dabigatran have shown greater be…
View article: Healthcare Resource Use and Cost Associated with Negative Symptoms of Schizophrenia
Healthcare Resource Use and Cost Associated with Negative Symptoms of Schizophrenia Open
Introduction Schizophrenia is a chronic neurodevelopmental disorder characterized by positive, negative, and cognitive symptoms. While current antipsychotic (AP) medications are generally effective in treating positive symptoms, they don’t…
View article: Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis
Seroresponse to third doses of SARS-CoV-2 vaccine among patients receiving maintenance dialysis Open
Given the increased morbidity and mortality from COVID-19 among patients undergoing maintenance dialysis, we examined the seroresponse to an additional dose of SARS-CoV-2 mRNA vaccine, using a hypothesized protective anti-spike protein IgG…
View article: SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients
SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients Open
Background SARS-CoV-2 vaccine effectiveness during the Delta period and immunogenicity threshold associated with protection against COVID-19 related hospitalization or death in the dialysis population is unknown. Methods A retrospective, o…
View article: Seroresponse to Inactivated and Recombinant Influenza Vaccines among Maintenance Hemodialysis Patients
Seroresponse to Inactivated and Recombinant Influenza Vaccines among Maintenance Hemodialysis Patients Open
Rationale & Objectives High dose influenza vaccine provides better protection against influenza infection in older adults than standard dose vaccine. We compared vaccine seroresponse among hemodialysis patients over 4 months after high dos…
View article: SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients
SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients Open
Among patients receiving maintenance dialysis with a national US dialysis provider, fully vaccinated dialysis patients were significantly less likely to be diagnosed with COVID-19 or be hospitalized than unvaccinated patients. Ad26.COV2.S/…
View article: Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over six months
Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over six months Open
Background and Objectives While most maintenance dialysis patients exhibit initial seroresponse to vaccination, concerns remain regarding the durability of this antibody response. This study evaluated immunity over time. Design, setting, p…
View article: Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients
Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients Open
Importance Vaccines against SARS-CoV-2 are highly effective in the general population; however, their efficacy may be diminished in maintenance dialysis patients, a population particularly vulnerable to COVID-19 infection and morbidity. Ob…
View article: Immunogenicity of SARS-CoV-2 Vaccine in Dialysis
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis Open
Significance Statement In this retrospective observational evaluation of SARS-CoV-2 mRNA vaccine seroresponse defined by levels of Ig-G against the receptor-binding domain of the S1 subunit of SARS-CoV-2 spike antigen ≥2 U/L in patients re…
View article: Epidemiology and Outcomes of COVID-19 in Home Dialysis Patients Compared with In-Center Dialysis Patients
Epidemiology and Outcomes of COVID-19 in Home Dialysis Patients Compared with In-Center Dialysis Patients Open
Patients on dialysis are particularly vulnerable to coronavirus disease 2019 (COVID-19), with multiple studies describing mortality >20%.12–3 Although infection rates among patients on dialysis tend to parallel local patterns, this populat…
View article: Immunogenicity of SARS-CoV-2 Vaccine in Dialysis
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis Open
Background Patients receiving maintenance dialysis represent a high risk, immune-compromised population with 15-25% COVID mortality rate who were unrepresented in clinical trials evaluated for mRNA vaccines’ emergency use authorization. Me…
View article: Clinical Topic Review 2013 - Behavioral Health Screening Among MassHealth Children and Adolescents
Clinical Topic Review 2013 - Behavioral Health Screening Among MassHealth Children and Adolescents Open
Results from the 2013 evaluation suggest that the Children’s Behavioral Health Initiative had a large impact on formal behavioral health screening and treatment utilization among children and adolescents enrolled in MassHealth.